Oramed Pharmaceuticals Announces Completion of Patient Enrollment for Pivotal Phase 2B Clinical Trials of ORMD-0801
– Key Trial for Oral Insulin With Expected Results at the End of Q1 of
2010
Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) announced today the
completion of patient enrollment in the Phase 2B clinical study of its oral
insulin capsule, ORMD-0801. The last of the thirty Type II diabetes patients
was enrolled for a study in which subjects will be administered the
insulin-based capsule for a period of six weeks.
The randomized, double-blind, placebo-controlled, multi-centered study
will evaluate the safety, tolerability, and efficacy of Oramed’s oral insulin
delivery technology. The study is taking place in five locations throughout
organization (CRO) based in
expected by the end of first quarter of 2010.
This trial marks an important milestone in ORMD-0801 safety testing,
assessing the first indication of ORMD-0801 on a large group of volunteers
over an extended treatment period.
“The closing of enrollment for the Phase 2B trial is an exciting
accomplishment for us, as it moves us closer to completing this trial and
receiving the results. In the upcoming months, we look forward to being able
to share the results from the trial, which will mark a major milestone in the
development of oral insulin,” explained
Pharmaceuticals.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule currently in
Phase 2 clinical trials. Established in 2006, Oramed’s technology is based on
over 25 years of research performed by top research scientists at
Hadassah Medical Center. The Company’s corporate and R&D headquarters are
based in
For more information, please visit http://www.oramed.com
Safe Harbor Statement
Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks
and uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or delays in
obtaining regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company’s ability to
obtain additional funding required to conduct its research, development and
commercialization activities. Please refer to the company’s filings with the
Securities and Exchange Commission for a comprehensive list of risk factors
that could cause actual results, performance or achievements of the company
to differ materially from those expressed or implied in such forward looking
statements. The company undertakes no obligation to update or revise any
forward-looking statements.
Source: Oramed Pharmaceuticals, Inc.
Company and Investor Relation Contacts:
Oramed Pharmaceuticals
Tara Horn
Cell: +972-54-334-318
Office: +972-2-566-0001
Email: tara@oramed.com
SOURCE Oramed Pharmaceuticals Inc.